Boston Scientific Corporation

NYSE:BSX

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🧬 Biotechnology

🔬 Clinical Trials

💻 Telehealth

Location

United States

Market Cap

USD 149.87 B

Share Price

USD 101.30

Avg Daily Volume

8,321,877

Change (1 day)

-0.07%

Change (1 year)

31.56%

Change (YTD)

13.41%

Boston Scientific Corporation Total Liabilities for the year ending December 31, 2024: USD 17.39 B

Boston Scientific Corporation Total Liabilities is USD 17.39 B for the year ending December 31, 2024, a 11.44% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Boston Scientific Corporation Total Liabilities for the year ending December 31, 2023 was USD 15.61 B, a 4.77% change year over year.
Boston Scientific Corporation Total Liabilities for the year ending December 31, 2022 was USD 14.90 B, a -4.56% change year over year.
Boston Scientific Corporation Total Liabilities for the year ending December 31, 2021 was USD 15.61 B, a 1.01% change year over year.
Boston Scientific Corporation Total Liabilities for the year ending December 31, 2020 was USD 15.45 B, a -7.41% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

NYSE: BSX

Boston Scientific Corporation

CEO	Mr. Michael F. Mahoney
IPO Date	May 19, 1992
Location	United States
Headquarters	300 Boston Scientific Way
Employees	53,000
Sector	🏥 Health Care
Industries Medical Instruments 🧬 Biotechnology 🔬 Clinical Trials 💻 Telehealth

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.